Vaxcyte, Inc. (NASDAQ:PCVX) Shares Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. grew its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 0.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 51,136 shares of the company’s stock after acquiring an additional 296 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned about 0.05% of Vaxcyte worth $3,211,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Russell Investments Group Ltd. acquired a new stake in shares of Vaxcyte in the 1st quarter worth $30,000. Avior Wealth Management LLC acquired a new stake in shares of Vaxcyte in the 3rd quarter worth $178,000. Wells Fargo & Company MN increased its stake in shares of Vaxcyte by 162.5% in the 4th quarter. Wells Fargo & Company MN now owns 3,961 shares of the company’s stock worth $190,000 after acquiring an additional 2,452 shares during the last quarter. Osaic Holdings Inc. increased its stake in shares of Vaxcyte by 59.9% in the 2nd quarter. Osaic Holdings Inc. now owns 4,073 shares of the company’s stock worth $200,000 after acquiring an additional 1,526 shares during the last quarter. Finally, Creative Planning acquired a new stake in shares of Vaxcyte in the 4th quarter worth $205,000. 96.78% of the stock is owned by institutional investors and hedge funds.

Vaxcyte Trading Up 0.3 %

NASDAQ PCVX opened at $62.43 on Thursday. The stock has a market cap of $6.77 billion, a PE ratio of -15.12 and a beta of 0.89. Vaxcyte, Inc. has a twelve month low of $40.74 and a twelve month high of $82.04. The stock has a fifty day simple moving average of $69.94 and a 200-day simple moving average of $60.85.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Tuesday, February 27th. The company reported ($1.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.93). During the same quarter in the prior year, the firm posted ($0.73) earnings per share. Research analysts predict that Vaxcyte, Inc. will post -4.18 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on PCVX. Bank of America raised their target price on Vaxcyte from $67.00 to $80.00 and gave the stock a “buy” rating in a research note on Tuesday, January 2nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a report on Friday, January 12th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $95.00 price target on shares of Vaxcyte in a report on Wednesday, April 10th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vaxcyte has an average rating of “Buy” and a consensus price target of $78.50.

Insider Activity at Vaxcyte

In related news, CEO Grant Pickering sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $63.92, for a total transaction of $958,800.00. Following the completion of the transaction, the chief executive officer now directly owns 375,814 shares in the company, valued at approximately $24,022,030.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, SVP Elvia Cowan sold 11,678 shares of Vaxcyte stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $74.08, for a total value of $865,106.24. Following the completion of the transaction, the senior vice president now owns 12,480 shares in the company, valued at approximately $924,518.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction dated Tuesday, January 23rd. The shares were sold at an average price of $63.92, for a total value of $958,800.00. Following the completion of the transaction, the chief executive officer now owns 375,814 shares of the company’s stock, valued at approximately $24,022,030.88. The disclosure for this sale can be found here. Insiders sold 101,577 shares of company stock worth $6,940,475 in the last three months. 3.60% of the stock is owned by company insiders.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.